DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
The poster
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER) , Abstract TPS2658
, will present CatalYm s first-in-human, two-part, open-label phase 1 clinical trial of CTL-002, a neutralizing antibody targeting GDF-15. GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment. In the GDFATHER-trial, patients with advanced-stage, solid tumors who have not responded or stopped responding to anti-PD-1/PD-L1 therapy are treated with CTL-002 as monotherapy and followed by combination with an anti-PD-1 antibody. The first patient was enrolled in December 2020.
MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that .
Share:
MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L Huillier brings over two decades of experience in executive leadership positions in the pharmaceutical and biotechnology industries, with an outstanding track record of success in the commercial development of businesses and partnerships. His experience reflects an international career in business, science, and academia.
Dr. Phil L Huillier joins CatalYm from a position as Head of the European Innovation Hub & Business Development at MSD (known as Merck & Co. in North America). In this position he was an active member of MSD global Business Development and Licensing Leadership as well leading a team of scientific and business development professionals that were focused on the identification, evaluation and development of
CatalYm Appoints Industry Leader Dr. Phil L'Huillier as Chief Executive Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.